STRO Sutro Biopharma Inc.

11.11
-0.6  -5%
Previous Close 11.71
Open 11.71
Price To Book 2.33
Market Cap 256,531,567
Shares 23,090,150
Volume 43,592
Short Ratio
Av. Daily Volume 71,383
Stock charts supplied by TradingView

NewsSee all news

  1. Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  2. Sutro Biopharma Appoints James Panek to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 8, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  3. Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  4. Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 19, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  5. Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments

    SOUTH SAN FRANCISCO, Calif., Nov. 8, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 presentation at ASH December 2019.
STRO-001
Non-Hodgkin lymphoma (NHL)
Phase 1 initial data noted 1/13 partial responses, 3 stable disease. Maximum tolerated dose not yet reached - October 29, 2019.
STRO-002
Ovarian and Endometrial Cancer

Latest News

  1. Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  2. Sutro Biopharma Appoints James Panek to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 8, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  3. Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  4. Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 19, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  5. Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments

    SOUTH SAN FRANCISCO, Calif., Nov. 8, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  6. Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein

  7. Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

    SOUTH SAN FRANCISCO, Calif., Oct. 8, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO) today announced that it has achieved a milestone under its collaboration and license agreement with the healthcare division of

  8. Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 4, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C. Wainwright 21st